Market Access, also known as Global Evidence, Value and Access, is the process used to ensure that all patients who are eligible to benefit from a specific treatment get access to it, at the appropriate price.
The process for healthcare companies in developing their market access strategy, requires both internal and external focus and investment, and is designed to meet the needs of the payer audience, Ministries of Health, and other key stakeholders. Core components include:
- Value Identification: How do we interpret value for the payer; is the product reasonable and necessary, in comparison to existing treatments?
- Value Creation: How do we define the value story through HEOR initiatives and data? How does the manufacturer incorporate HEOR metrics into the clinical trial study design?
- Value Communication: How do we communicate the value story to key stakeholders, i.e. development of a global HTA dossier.
The market access process is conducted as a global initiative that also addresses the needs of stakeholders at the local level. Global value dossiers (the key deliverable in market access – is developed in collaboration with target markets and across internal business functions) must be adapted to meet the needs of specific market access customers at both the national and local level, to address the unique aspects of each healthcare system.
YouthView: Understanding risk behaviours for meningococcal meningitis among young people
While meningococcal meningitis is relatively uncommon, it is unpredictable, may progress very rapidly and can lead to death in as little as 24 hours from the first symptoms.(1,2)
Although only a few of those exposed to the bacteria will actually develop disease, adolescents and young adults are more likely than any other age group to carry the bacteria without showing symptoms, with carriage rates peaking in 19 year olds with almost 1 in 4 (24%) carrying.(3)